SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 33 of 85
Word Count: 1481
Character Count: 10079

Document Content:

attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be adversely affected and more volatile. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS The information in this prospectus contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this prospectus other than statements of historical fact, including statements regarding our future operating results and financial position, our business strategy and plans, market growth, and our objectives for future operations, are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

You
can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “could,”
“would,” “expect,” “anticipate,” “aim,” “estimate,” “intend,”
“plan,” “believe,” “is/are likely to,” “potential,” “project,” “target,”
“continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain
these words. The forward-looking statements in this prospectus are only predictions and are based largely on our current expectations
and projections about future events and financial trends that we reasonably believe may affect our business, financial condition, and
results of operations. Although we believe the expectations reflected in any of our forward-looking statements are reasonable, actual
results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition
and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties.

These
forward-looking statements present our estimates and assumptions only as of the date of this prospectus and are subject to several known
and unknown risks, uncertainties, and assumptions. Accordingly, you are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the dates on which they are made. Except as required by applicable law, we do not plan to publicly update or revise
any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise.
Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are
not limited to, those summarized below:

●	failure
to obtain FDA approval to commercially sell our product candidates in a timely manner or at all;

●	failure
to carry out our trials on the timelines expected and with the expected efficacy or safety results;

●	whether
heart failure specialists, surgeons and patients in our target markets accept our product candidates, if approved;

●	the
expected growth of our business and our operations, and the capital resources needed to progress our business plan;

●	failure
to scale up of the manufacturing process of our product candidates in a timely manner, or at all;

●	failure
to manufacture our product candidates at a competitive price;

●	our
ability to retain and recruit key personnel, including the development of a sales and marketing infrastructure;

●	reliance
on third party suppliers for certain components of our product candidates;

●	reliance
on third parties to commercialize and distribute our product candidates in the United States and internationally;

●	changes
in external competitive market factors;

●	uncertainties
in generating sustained revenue or achieving profitability

●	unanticipated
working capital or other cash requirements;

●	changes
in FDA regulations, including testing procedures, of medical devices and related promotional and marketing activities;

●	our
estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional
financing;

●	estimates of our addressable market, market growth,
future revenue, expenses, capital requirements and our needs for additional financing;

●	our
ability to obtain and maintain intellectual property protection for our product candidates; and

●	changes
in our business strategy or an inability to execute our strategy due to unanticipated changes in the medical device industry.

The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or
risk factors that we are faced with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could
differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth above
under “Risk Factors” and elsewhere in this prospectus. All subsequent written and oral forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above
and throughout this prospectus. Prior to investing in our common stock, you should read this prospectus and the documents we have filed
as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual
future results may be materially different from what we currently expect.

USE
OF PROCEEDS

estimate that we will receive net proceeds from this offering of approximately $       million (or approximately $        million if the underwriters
exercise their over-allotment option in full), after deducting estimated offering expenses payable by us, and based upon an assumed initial
public offering price of $        per share, the midpoint of the estimated price range set forth on the cover page of this prospectus.

intend to use the net proceeds from this offering as follows:

●	approximately
$           (or approximately $      million if the underwriters
exercise their over-allotment option in full), or approximately 60% of the net proceeds from this offering, to fund the RELIVE
Trial and the associated manufacturing activities required to support such trial; and

●	approximately
$           (or approximately $      million if the underwriters
exercise their over-allotment option in full), or approximately 40% of the net proceeds from this offering, for working capital
and other general corporate purposes, including regulatory compliance, intellectual property protection, additional employee hires
and additional contractor retainment.

Assuming the offering generates approximately $15.0 million in gross proceeds, we believe these funds will be sufficient
to achieve full site engagement, enroll approximately 75% of patients, and complete patient enrollment within approximately three months
thereafter.

$1.00 increase (decrease) in the assumed initial public offering price would increase (decrease) the net proceeds to us from this offering
by approximately $           million, after deducting the estimated underwriting discounts,
non-accountable expense allowance and estimated aggregate offering expenses payable by us and assuming no change to the number of shares
of common stock offered by us as set forth on the cover page of this prospectus.

We may change the amount of net proceeds to be used
specifically for any of the foregoing purposes. The amounts and timing of our actual expenditures will depend upon numerous factors,
including factors within our discretion and factors outside of our control. We may also use a portion of the net proceeds to acquire,
license and invest in complementary product candidates, technologies, or additional businesses; however, we currently have no agreements
or commitments with respect to any such transaction.

Moreover,
the foregoing represents only our current
intentions based upon our present plans and business conditions to allocate and use the net proceeds from this offering. You are cautioned
that the nature, amounts and timing of our actual expenditures may vary significantly from what is described above or elsewhere
in this prospectus depending on numerous factors. As a result, our management has and will retain broad discretion over the allocation
of the net proceeds from this offering. We may find it necessary or advisable to in our business judgement to use the net proceeds
from this offering for other purposes. Also, if an unforeseen event occurs or business conditions change, we may use the proceeds
of this offering differently than as described above or elsewhere in this prospectus.

Pending our use of the net proceeds from
this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade,
interest-bearing instruments, and U.S. government securities.

addition, as a general matter, given our limited
operating history, early stage of business and a new and unproven technology model, it is difficult to evaluate our business prospects
and actual expenditures in the future. Further, our business plan will be very costly, far more costly than the net proceeds we will
receive from this offering. To develop and implement our business as currently planned, we will need to raise substantial amounts of
additional capital and we intend to raise such additional capital through public or private offerings of equity or equity-linked securities,
traditional loans, commercial collaborations such as licenses or joint ventures and, if available or desirable, government funding, including
grants. No assurances can be given that we will be able to raise additional capital when needed, and our inability to raise additional
capital could lead to the failure of our company.

DIVIDEND
POLICY